Sudden aggravated CD8⁺ mycosis fungoides accompanied by hidden adenocarcinoma of the colon



Hye-Jin Ahn, MD, Eun Jae Shin, MD, Min-Jae Gwak, MD, Ki-Heon Jeong, MD, PhD, and Min Kyung Shin, MD, PhD Seoul, Korea

Key words: CD8+ mycosis fungoides; colon adenocarcinoma; cutaneous T-cell lymphoma; hidden malignancy; mycosis fungoides; paraneoplastic syndrome.

INTRODUCTION

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL). The neoplastic T cells in MF are usually mature CD4⁺ T cells, and CD8⁺ phenotype expression is rarely observed.¹ There are 2 categories of CD8⁺ CTCL, one with aggressive behavior and one with indolent behavior.² We report a rare case of suddenly aggravated CD8⁺ MF that was found to be associated with a hidden adenocarcinoma in the colon.

CASE REPORT

A 40-year-old woman visited our clinic because of erythematous and poikilodermatous patches of various sizes on the extremities and trunk of 1 years' duration (Fig 1, A through D). The affected body surface area was calculated by 2 dermatologists to be 40%. Skin biopsy examination of the lesions indicated atypical lymphocytes that were surrounded by a clear halo located along the dermoepidermal junction and on the epidermis (Fig 2, A and B). The skin lesions remained stationary during low-dose systemic steroid treatment. However, they were suddenly aggravated and increased size, and vegetative plaques were seen 2 months later (Fig 3, Bthrough D). Because of the aggravation of the lesions, an additional skin biopsy found similar features of the previous condition (epidermotropism with haloed cells). Immunohistochemical analysis found CD4 negativity and CD8, CD30, and Ki-67 positivity (Fig 2, C and D). Monoclonality of the Tcell receptor gene rearrangement was found, and

	4bbi	eviations	used:
--	------	-----------	-------

CTCL: cutaneous T-cell lymphoma FOLFOX: folinic acid, fluorouracil, oxaliplatin MF: mycosis fungoides

CD8⁺ MF was diagnosed. Although the patient had been treated with phototherapy, a systemic retinoid, and methotrexate for 2 months, the skin lesions were more aggravated and had a thick crust with eroded and vegetative plaques. The patient underwent further examinations to determine systemic involvement of extracutaneous lymphoma. Bone marrow biopsy results showed no evidence of lymphoma involvement, but a sigmoid colon mass was detected by abdominal computed tomography (Fig 3, A); biopsy of the mass found an adenocarcinoma. Stage IIIc sigmoid colon cancer with stage IB of MF was finally diagnosed and she underwent surgical resection and treatment with 12 cycles of FOLFOX chemotherapy (folinic acid, fluorouracil, oxaliplatin). After colon cancer treatment, the aggravated skin lesions improved and the vegetative plaques resolved to brownish patches, similar to their appearance during the first visit. Since then, her MF has been well controlled with phototherapy.

DISCUSSION

MF is the most common type of CTCL. It is clinically categorized in patch, plaque, and tumor stages. During the early patch stage, there are single or multiple erythematous macules and patches that vary in size and

From the Department of Dermatology, School of Medicine, Kyung Hee University.

Funding sources: None.

Conflicts of interest: None declared.

Correspondence to: Min Kyung Shin, MD, PhD, Department of Dermatology, School of Medicine, Kyung Hee University, Kyung hee daero23, Dongdaemun-gu, Seoul 02447, Republic of Korea. E-mail: haddal@hanmail.net.

JAAD Case Reports 2017;3:83-6.

²³⁵²⁻⁵¹²⁶

^{© 2016} by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

http://dx.doi.org/10.1016/j.jdcr.2016.12.003



Fig 1. Multiple erythematous and poikilodermatous patches on the entire body.

color.¹ Histologically, the epidermis shows epidermotropism, which comprises small to medium atypical lymphocytes with enlarged hyperchromatic and clear cytoplasm (haloed cells). The neoplastic T cells in MF are usually mature CD4⁺ T cells, and approximately 20% of cases of early MF involve the CD8⁺ phenotype.² The clinical behavior of CD8⁺ MF is similar to that of the CD4⁺ type, which is indolent.¹ The condition may remain in the early patch stage or plaque stage for months or years before progressing to the tumor stage. Therefore, the diagnosis of early-stage MF is often challenging because of its overlapping clinical and histologic findings with various reactive dermatoses.¹ In contrast to the indolent course, according to the World Health Organization— European Organisation for Research and Treatment of Cancer classification,² there are CD8⁺ cutaneous lymphomas with aggressive behavior and poor prognoses that are categorized as primary aggressive epidermotropic CD8⁺ cytotoxic CTCL.

Download English Version:

https://daneshyari.com/en/article/5646206

Download Persian Version:

https://daneshyari.com/article/5646206

Daneshyari.com